Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Target discovery.

Mark A Lindsay1

  • 1AstraZeneca Pharmaceuticals, 19F19 Alderley Park, Macclesfield, Cheshire SK10 4TG, UK. mark.lindsay@astrazeneca.com

Nature Reviews. Drug Discovery
|October 4, 2003
PubMed
Summary
This summary is machine-generated.

Identifying and validating disease targets is crucial for drug discovery. This review examines current strategies and new technologies like genomics and proteomics for finding effective disease-modifying proteins.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Catalogue of LPS-induced transcriptional changes across vertebrates identifies syntenically conserved human long non-coding RNAs that regulate the innate immune response.

Frontiers in immunology·2026
Same author

Antimicrobial effects and mechanisms of hydrogen sulphide against nail pathogens.

Scientific reports·2025
Same author

Exercise without Weight Loss Prevents Seasonal Decline in Vitamin D Metabolites: The VitaDEx Randomized Controlled Trial.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025
Same author

Electrochemical microfluidic biosensor for the detection of CD4<sup>+</sup> T cells.

Microsystems & nanoengineering·2025
Same author

Obesity defined molecular endotypes in the synovium of patients with osteoarthritis provides a rationale for therapeutic targeting of fibroblast subsets.

Clinical and translational medicine·2023
Same author

Long Non-coding RNAs in Rheumatology.

Advances in experimental medicine and biology·2022
Same journal

R&D productivity trends for biopharma companies in Asia and emerging markets.

Nature reviews. Drug discovery·2026
Same journal

Growth in clinical research capability in China and impact on the pharmaceutical sector.

Nature reviews. Drug discovery·2026
Same journal

Circular RNA guides exon skipping in DMD.

Nature reviews. Drug discovery·2026
Same journal

p38α inhibition restores axonal transport.

Nature reviews. Drug discovery·2026
Same journal

Inflammatory bowel disease-on-a-chip.

Nature reviews. Drug discovery·2026
Same journal

Designing GPCR-targeted miniproteins.

Nature reviews. Drug discovery·2026
See all related articles

Area of Science:

  • Biochemistry
  • Genetics
  • Pharmacology

Background:

  • Drug discovery relies on identifying disease-modifying targets.
  • The human genome project has accelerated research into protein function.
  • Effective target identification and validation are critical for therapeutic development.

Purpose of the Study:

  • To critically examine strategies for identifying and validating disease-relevant proteins.
  • To assess the impact of recent technological advancements on target discovery.
  • To speculate on future trends in the field.

Main Methods:

  • Review of existing literature and methodologies.
  • Analysis of technological advances including genomics and proteomics.
  • Examination of small interfering RNA and mouse knockout models.

Related Experiment Videos

Main Results:

  • Genomics and proteomics offer powerful tools for target identification.
  • RNA interference and knockout models are key for target validation.
  • Technological integration enhances the efficiency of target discovery.

Conclusions:

  • Strategic application of new technologies is vital for successful drug discovery.
  • Continued innovation in target validation methods is necessary.
  • Future trends point towards integrated, multi-omics approaches for identifying novel therapeutic targets.